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The Medical Schemes Act and its Regulations1 define 
managed health care as ‘clinical and financial risk assessment 
and management of health care, with a view to facilitating 
appropriateness and cost effectiveness within the constraints 
of what is affordable, through the use of rules-based and 
clinical management-based programmes’. The Regulations1 
further indicate that such management should incorporate 
evidence-based medicine, defined as ‘the conscientious, 
explicit and judicious use of current best evidence in making 
decisions about care of beneficiaries’.  With these definitions 
in mind, health risk managers within Medscheme’s Managed 
Care Division (subsequently known as Solutio Health 
Risk Management) introduced several preventive health 
programmes in 2003. The first two programmes were based 
on results of in-house research that showed an increased hip 
fracture risk in premenopausal women who had suffered 
minor fractures2 and also in long-term users of corticosteroids.3 
These initiatives involved communication with identified high-
risk members, and the recommendation that the possibility of 
fracture should be discussed with their health care provider/s.  
A third programme identified long-term users of anticoagulant 
therapy who were not submitting claims for monitoring of 
coagulation status, drew their attention to the clinical risks 
associated with over- or under-treatment, and recommended 
discussion of the situation with their managing doctor/s.
These programmes were generally appreciated by members 
of the participating medical schemes and by their doctors, and 
as a result, trustees of the schemes encouraged Medscheme to 
explore additional preventive health programmes that would 
benefit their members. Of several possibilities discussed, the 
one that captured the trustees’ imagination was a screening 
programme for the presence of abdominal aortic aneurysm 
(AAA).  Trustees had been drawn to this topic by media 
reports and corporate experiences of productive (often top-
level) employees succumbing to rupture of a previously 
unrecognised aneurysm. Medscheme was therefore requested 
to review the literature and, if indicated, develop an evidence-
based managed care pilot programme for the prevention of 
AAA-related morbidity and mortality.  International literature 
emerging at the time was showing evidence of the cost 
effectiveness of mass screening, and the decision was taken to 
proceed with the pilot study after consultation with practising 
national experts in the fields of vascular surgery and radiology.  
Discussions took place with senior members of the Vascular 
and Radiological Societies, leading to the decision that the 
pilot study would focus on male subjects considered to be at 
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Objective. A pilot study to assess the feasibility and affordability 
of a targeted screening programme for abdominal aortic 
aneurysms in a group of employer-based medical schemes.
Design. Administrative database review and data extraction.  
Member enrolment by mail. Analysis using simple descriptive 
statistics.  Review of international experience
Outcome measures. Screening uptake and findings, type and cost 
of interventions recommended by providers.
Results. Database review identified 2 187 age-eligible subjects 
(males between 60 and 65 years) who were advised to consult 
with their doctor/s if they had a history of smoking/and or 
cardiovascular disease. Two hundred and seven were referred 
for abdominal ultrasound screening, and aneurysms ≥ 3.0 cm 
were found in 11 (5.3%). Only 1 subject had an aneurysm of 
sufficient size to justify early surgical intervention, and which 
resulted in the patient’s death.  Total cost of this pilot study 
approached R1 million.  Analysis indicated that the sampling 
rate would have to be increased if such a programme were to 
be introduced as a routine medical benefit.
Conclusions.  International experience has been that screening 
for abdominal aortic aneurysms reduces morbidity and 
mortality but at a significant cost.  Opinion of the researchers 
and trustees of the participating medical schemes was that 
this cost would be beyond the means of schemes at this time.  
Screening programmes, particularly those that increase health 
care costs in the early phases by identifying subjects for costly 
interventions, are unlikely to enjoy support as long as the 
health funding environment maintains its focus on short-term 
costs and benefits.
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risk for AAA, i.e. over 60 years of age, current or ex-smokers, 
and with a history of hypertension and/or cardiovascular 
disease.  Within the group of medical schemes administered 
by Medscheme, the pilot study was confined to six restricted 
(employer-based) medical schemes that had shown most 
interest in analysing the situation within their organisations.
Subjects and methods
While reported studies have included subjects as young as 50 
years of age4 and as old as 80,5 the focus in the participating 
medical schemes was on preventing morbidity and mortality 
during later years of employment.  Trustees and health risk 
managers therefore decided to selectively target men between 
the ages of 60 and 65 years.  The participating medical schemes 
included three major manufacturing/production organisations, 
one construction company, a large retail sales and distribution 
network, and a major academic institution.  Total membership 
for the schemes stood at 113 759 at the beginning of 2004 when 
the database was interrogated for eligible subjects.
The database search identified 2 187 age-eligible subjects 
who then received letters explaining what AAAs are, and 
indicating that even large aneurysms may be asymptomatic 
and undetected by patients and their doctors.   The set of 
risk factors was also presented, and those who fulfilled the 
criteria for risk and who were not already being investigated 
or treated for AAA were invited to consult with their doctor 
for referral for abdominal ultrasound if deemed necessary. 
The Radiological Society had already advised its members of 
the study and requested that to contain costs, investigation 
should be confined to the abdominal ultrasound examination 
wherever possible.  Onward referral to a vascular surgeon 
was requested in cases that required specialist opinion or 
follow-up, or in which surgery appeared to be necessary.  As 
per the literature, aortic dilatation ≥ 3.0 cm was regarded as 
being aneurysmal, with 3.0 - 4.5 cm considered small, 4.5 - 5.4 
cm intermediate, and ≥ 5.5 cm large and probably in need of 
repair.6 
The letter to targeted individuals included reply forms for 
radiologists and vascular surgeons.  These forms captured 
the necessary provider and patient details and were returned 
to Medscheme by post, e-mail or fax.  Radiologists and/or 
vascular surgeons were contacted if information was missing 
or patient follow-up was required.  Analysis of the results 
involved simple descriptive statistics.
Results
Of the 2 187 beneficiaries who fell into the 60 - 65-year category 
(1.9% of participating scheme membership), 207 were referred 
for abdominal ultrasound (9.5% of those contacted). AAAs 
≥ 3.0 cm were reported in 11 respondents (5.3% of those 
screened). Dilatation ≥ 3.0 cm was generally regarded by 
radiologists as being significant, although a small number in 
the 2.5 - 3.0 cm range were reported as being of concern and 
worthy of follow-up.  Details of the aneurysms and associated 
ultrasound findings are given in Table I.  
Early surgery was considered necessary in only 1 case 
of AAA, the rest being assigned to follow-up programmes 
according to the aortic diameter and estimated degree of 
risk.  Unfortunately the case in which surgery was performed 
was found to be more serious and complicated than had 
appeared at the time of abdominal ultrasound.  At operation 
the aneurysm was found to extend from the renal vessels to 
the aortic bifurcation, and the diameter was significantly larger 
than initially thought (7.5 cm rather than the report of 5.5 cm).  
Attempts at repair were followed by femoral artery thrombosis, 
limb amputation and renal failure, with the patient eventually 
succumbing. Total cost for the treatment of this patient at the 
Table I.  Study sample and results
Total membership of participating medical schemes (N) 113 759
Number eligible to receive letters (male, 60 - 65 years, active or 
past smoker, cardiovascular disease including hypertension, no 
known AAA)
2 187 (1.9% of membership of participating medical schemes)
Average age of group contacted 62.7 years
Number referred for screening 207 (9.5% of those contacted)
Number of aneurysms found
Small
Intermediate
Large
11 (5.3% of those screened) 
5
5
1
Other pathology identified at time of screening:
Aorta tortuous/calcified/atheromatous
Renal cysts/calcification/hydronephrosis
Fatty liver/cysts/gallstones
Enlarged prostate
73
35
12
19
7
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time of data collection was in excess of R350 000.  
Taking the costs of the above case as well as those of data 
extraction and member communication (total ±R17 500) 
and consultations, ultrasound examinations and referrals to 
vascular surgeons (total ±R647 000), the approximate cost per 
contacted study subject was R450.  As an annualised fee paid 
monthly by all members of the participating medical schemes, 
this translates to ±R2 per member per month (pmpm).  To these 
costs one would also have to add the cost of interventions 
for treatment of conditions found incidentally at the time of 
the AAA screen (e.g. cholecystectomy for gallstones) and the 
cost of follow-up and subsequent AAA-related surgery in the 
group. However, because this study only covered a 12 - 15-
month period during which we made initial contact and then 
mainly recorded the presence or absence of aneurysms and any 
coexisting conditions, no other procedures were undertaken 
during the period of review.  These important costs are 
therefore not included in this analysis.
For the most part, participants and their doctors were 
complimentary and appreciative of the trustees’ interest and 
initiative in implementing this pilot study.  Beneficiaries who 
screened negative were reassured by this knowledge, while 
those with an AAA were generally grateful for the warning and 
the chance to modify lifestyle in order to reduce cardiovascular 
risk.  On the other hand, trustee and member perceptions of 
the programme were less positive in the case of the previously 
functional and apparently well individual who died following 
elective surgery.  There were also concerns from some members 
above the 65-year age cut-off who, on hearing about the 
programme from colleagues, felt discriminated against and 
ignored by the medical scheme.
Discussion
Data produced over the past few years and summarised in 
Table II indicate that AAA affects between 4% and 8% of males 
over the age of 65 in a number of countries. Most AAAs are 
asymptomatic, but a percentage will dissect and/or rupture 
without warning. Less than 50% of patients with AAAs that 
rupture will reach hospital alive;7 emergency surgery in these 
patients not only costs ±70% more than elective surgery,8 but 
there is also an 8 - 10-fold increase in postoperative mortality 
risk.7 These statistics apply to the most severe cases of AAA; at 
the other extreme one has a majority of males who are either 
aneurysm-free or have aneurysms that will remain silent until 
death from other causes.  Study data indicate that overall risk 
of rupture for AAAs picked up by screening is between 6% and 
13% (Table II).
Large-scale randomised, controlled studies have been carried 
out to explore the cost effectiveness of abdominal ultrasound 
screening for AAA. Most of the studies have followed subjects 
for at least 4 - 5 years, while some have continued to report 
on outcomes for 10 - 13 years.4,8 In general, based on norms 
such as overall reduction in AAA-related mortality, the cost 
of preventing one death or the cost per life-year gained, 
researchers and policy-makers have come out on the side of 
screening being cost effective, with increasing effectiveness 
demonstrated as the period of follow-up is extended.4-9 
However it is important to appreciate that to save the lives 
of AAA victims, health care funders must be prepared for 
substantial increases in elective surgery rates.  Several of the 
patients who undergo surgery would not otherwise have died 
an AAA-related death, while a small number would rupture 
anyway and not make it to hospital for treatment.  Trustees 
of medical schemes that wish to introduce AAA screening 
therefore face a difficult decision, i.e. they must either load 
general membership with a contribution increase to cover a 
condition that affects < 5% of members, or they must cover 
the costs of the AAA screening programme by reallocating 
funds that are already being used to treat other (and more 
prevalent) conditions that affect this age group, e.g. coronary 
artery procedures and hip replacements. Our view is that 
in the medical schemes environment, if the health economic 
analyses had shown this to be a cost-minimising intervention 
then trustees would have no hesitation in proceeding with 
such a programme. However, as the health economic data have 
emerged, the cost implications are simply too great and AAA 
screening appears to be beyond the means of medical schemes 
at this time.  In this pilot study the negative experience of an 
unexpected and costly death following elective surgery for an 
AAA only added to the sense that implementation of screening 
would be risky and not in the best interests of scheme reserves 
and solvency.
Based on the early results of screening studies that were 
emerging at the time of implementation of this pilot study, 
and in anticipation of fairly high costs of the AAA screening 
programme, we sought to reduce costs by studying only a 
sub-set of highest-risk members.  Criteria for selection were 
discussed with practising experts in the fields of radiology and 
vascular surgery.  By specifying multiple entry and eligibility 
criteria, others11,12 have demonstrated fairly good results (±75% 
of aneurysms detected by selectively screening 20 - 50% of 
age-eligible subjects); however in our case we do not seem 
to have selected a sub-group with an AAA prevalence much 
higher than has been observed in large-scale screening studies 
from a number of countries (Table II).  This implies either 
that the risk criteria lacked specificity or that members who 
went for screening did so because of a general interest in their 
health rather than concern about the presence of specific risk 
factors.  Whatever the reason/s, the result is that to be effective 
in any future programme one would have to increase the 
numbers screened beyond the 9.5% screened in the pilot study.  
This would also add to the cost base, and this issue further 
discouraged trustees from implementing AAA screening as a 
routine benefit.  
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The third argument against future routine implementation 
of a screening programme for AAA arose out of the decision 
in the pilot phase to screen only within an age-eligible 
group (i.e. between 60 and 65).  Trustees of employer-based 
medical schemes are always sensitive to negative perceptions, 
particularly if they come from senior employees within the 
organisation.  As already stated, concerns were raised by 
some scheme members who were above the cut-off age of 65 
and who resented the fact that they had not been included.  
Addressing this by extending the age limits for an AAA 
screening programme would again add to the cost and further 
reduce affordability.
The final issue as one explores the feasibility of a costly 
screening programme in the South African medical schemes 
industry relates to the nature of that environment.  Clearly 
demonstrated by the longer-term follow-up studies of AAA 
screening is the increasing cost effectiveness over time,4-9 i.e. 
one spends the funds during the early post-screening phases 
and subsequently reaps the rewards of greater awareness 
and preventive interventions rather than costly emergency 
procedures for advanced catastrophic disease.  However, 
medical schemes in South Africa typically have a short-term 
focus (often only 1 year) related to financial considerations, 
rather than a long-term perspective on the health status of 
their membership. Even with the reforms of the 1998 Medical 
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Table II. Summary of AAA screening data
Measures Result References
Number of subjects studied 4 404 - 67 800 4, 5, 7, 9
Age range of participants 50 - 83 years
(mostly 65 - 75 years)
4, 5, 7, 9
Duration of follow-up 4 - 13 years
(mostly ±5 years)
4, 5, 7, 9
Prevalence of AAA 4 - 7.6% 4, 5, 6, 7, 9
Aneurysm diameter (cm)
Small (3.0 - 4.4)
Intermediate (4.5 - 5.4)
Large (≥ 5.5)
71%
17%
12% 
6
 Aneurysm rupture risk (data mostly for ±5- 
year follow-up period)
Small
Intermediate
Large
3%
15%
65%
6
Impact of AAA screening programmes 
Elective surgery rate
Emergency surgery rate
Rupture rate
AAA-related death rate
170 - 250% increase
50 - 75% decrease
49 - 55% decrease
42 - 75% decrease
7, 9, 10
7, 9
4, 5
4, 7, 9
Health economic analyses
Number screened to prevent 1 death
 Incremental costs (screening, follow-up, 
elective procedures)
Cost per life-year gained
 
325 - 710 (1 380 if screening from age 50) 
176% increase
 
 R300 000 plus at 5 years (converting US$ 
and British £ to rands), decreasing to     
±R100 000 by 10 years
4, 7, 9
7
7, 9
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Schemes Act that re-introduced minimum benefits and 
community-rating (everyone on the same benefit package pays 
the same rate, regardless of age or state of health), funders 
have competed for younger and healthier members. This 
strategy gives a lower community rate, and assists medical 
schemes in attracting members in the highly competitive open 
scheme environment in which brokers actively move members 
from one scheme to another.  This short-termism permeates the 
entire private health care funding industry, as even employer-
based schemes need to remain competitive against the much 
larger and aggressive open schemes. If they do not then brokers 
are more able to persuade union membership and other 
employees to move to an open scheme.  The Risk Equalisation 
Fund (REF)1 due to be implemented between medical schemes 
by the Department of Health in 2007 will reduce competition 
based on the selection of good risks. Medical schemes will pay 
equally into the REF according to beneficiary numbers, but 
will receive amounts according to the age and disease profile 
of their membership. The most successful schemes in future 
will be those that can most efficiently deliver health care to 
their members.  However it will also be necessary to limit the 
turnover of members between medical schemes and to provide 
an enabling environment in which scheme trustees can make 
decisions based on the long-term health of their members. Only 
then will programmes that identify clinical risk and treat the 
conditions early make financial as well as clinical sense to the 
funders. 
Conclusions
While literature published over the past 4 - 5 years has shown 
that screening for AAA significantly reduces AAA-related 
morbidity and mortality, this comes at a considerable cost 
which, at this time, would probably be unaffordable for most 
medical schemes in South Africa.   Perhaps a more important 
issue is that of the short-term orientation of health care 
funders.  As long as attention is on short-term financial results 
rather than the long-term health of membership, programmes 
such as AAA screening are unlikely to receive much attention 
from medical schemes. The role of the REF in incentivising 
funders to consider cost-effective delivery of health care will 
help to alter the balance in favour of preventive care, but 
turnover of members between medical schemes will also need 
to be addressed.
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The SAMJ has been available online for some years 
through the SAMA website and elsewhere, such as 
through PubMed. We are pleased to announce that plans 
are well advanced with a new manuscript management 
system that will enable authors to submit their papers 
online directly to the Journal. This process will also 
significantly enhance the subsequent passage of 
manuscripts through the system. Further details will be 
provided shortly and authors will be prompted.
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